{"disease":{"id":"t-cell","name":"t cell"},"drugs":{"marketed":[{"drug_id":"nivolumab","indication_name":"Transitional cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opdivo","generic_name":"nivolumab","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"9200","mechanism":"Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells."},{"drug_id":"nivolumab","indication_name":"Advanced melanoma with tumour cell PD-L1 expression below 1%","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opdivo","generic_name":"nivolumab","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"9200","mechanism":"Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells."},{"drug_id":"nivolumab","indication_name":"Metastatic renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opdivo","generic_name":"nivolumab","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"9200","mechanism":"Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells."},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with sickle cell disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"lenalidomide","indication_name":"Mantle cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Revlimid","generic_name":"lenalidomide","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Cereblon (component of cullin ring E3 ubiquitin ligase enzyme complex)","drug_class":"Thalidomide analogue","quality_score":10,"revenue":"5809","mechanism":"Lenalidomide targets cereblon to degrade substrate proteins, inducing cytotoxicity and immunomodulation."},{"drug_id":"osimertinib","indication_name":"Adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tagrisso","generic_name":"osimertinib","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":67,"revenue":"5800","mechanism":"Osimertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that binds irreversibly to mutant forms of EGFR."},{"drug_id":"upadacitinib","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Giant cell arteritis in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"durvalumab","indication_name":"Extensive stage primary small cell carcinoma of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imfinzi","generic_name":"durvalumab","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"Programmed Death Ligand-1 Blocker [EPC]","quality_score":10,"revenue":"4900","mechanism":"Imfinzi works by blocking the PD-L1 protein, allowing the immune system to recognize and attack cancer cells."},{"drug_id":"durvalumab","indication_name":"Transitional cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imfinzi","generic_name":"durvalumab","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"Programmed Death Ligand-1 Blocker [EPC]","quality_score":10,"revenue":"4900","mechanism":"Imfinzi works by blocking the PD-L1 protein, allowing the immune system to recognize and attack cancer cells."},{"drug_id":"rituxan","indication_name":"Burkitt cell leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"rituxan","company_name":"Roche","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody","quality_score":45,"revenue":"3800","mechanism":""},{"drug_id":"rituxan","indication_name":"CD20 positive diffuse large B cell non Hodgkin's lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"rituxan","company_name":"Roche","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody","quality_score":45,"revenue":"3800","mechanism":""},{"drug_id":"atezolizumab","indication_name":"Transitional cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tecentriq","generic_name":"atezolizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"3700","mechanism":"Tecentriq works by blocking a protein called PD-L1, which helps cancer cells hide from the immune system."},{"drug_id":"atezolizumab","indication_name":"Metastatic non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tecentriq","generic_name":"atezolizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"3700","mechanism":"Tecentriq works by blocking a protein called PD-L1, which helps cancer cells hide from the immune system."},{"drug_id":"atezolizumab","indication_name":"Extensive stage primary small cell carcinoma of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tecentriq","generic_name":"atezolizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"3700","mechanism":"Tecentriq works by blocking a protein called PD-L1, which helps cancer cells hide from the immune system."},{"drug_id":"ibrutinib","indication_name":"Mantle cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imbruvica","generic_name":"ibrutinib","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase Blk","drug_class":"Kinase Inhibitor [EPC]","quality_score":74,"revenue":"3200","mechanism":"Imbruvica works by blocking the activity of a specific enzyme called Bruton's tyrosine kinase (BTK), which is involved in the growth and survival of cancer cells."},{"drug_id":"acalabrutinib","indication_name":"Mantle cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Calquence","generic_name":"ACALABRUTINIB","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase BTK","drug_class":"Kinase Inhibitor [EPC]","quality_score":59,"revenue":"3100","mechanism":"Calquence works by blocking the activity of the BTK enzyme, which is essential for the activation and survival of B cells."},{"drug_id":"ipilimumab","indication_name":"Metastatic nonsmall cell lung cancer with no sensitising EGFR mutation or ALK translocation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Yervoy","generic_name":"ipilimumab","company_name":"Bristol-Myers Squibb","drug_phase":"discontinued","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"CTLA-4-directed Blocking Antibody","quality_score":0,"revenue":"2900","mechanism":"Yervoy blocks a protein called CTLA-4, which normally helps to turn off the immune system, allowing it to attack cancer cells."},{"drug_id":"desonide","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Verdeso","generic_name":"DESONIDE","company_name":"Padagis Us","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":"2800","mechanism":""},{"drug_id":"bgb-3111","indication_name":"Mantle cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brukinsa","generic_name":"BGB-3111","company_name":"Beigene Usa Inc","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase BTK","drug_class":"Kinase Inhibitor [EPC]","quality_score":72,"revenue":"2700","mechanism":"Brukinsa blocks the BTK protein, which is involved in the activation of B cells."},{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor and have received at least one prior therapy.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor and have received at least one prior therapy and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor and have received at least one prior therapy and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor and have received at least one prior therapy and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor and have received at least one prior therapy and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor and have received at least one prior therapy and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor and have received at least one prior therapy and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor and have received at least one prior therapy and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor and have received at least one prior therapy and have failed a B-cell receptor (BCR) pathway inhibitor.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor and have received at least one prior therapy and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with CLL who are not eligible for or have failed a B-cell receptor (BCR) pathway inhibitor.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"cabometyx","indication_name":"Metastatic renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cometriq","generic_name":"Cabometyx","company_name":"Exelixis","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor receptor 2","drug_class":"Kinase Inhibitor","quality_score":70,"revenue":"2200","mechanism":"Cometriq blocks the VEGFR2 pathway to prevent tumor growth and angiogenesis."},{"drug_id":"bevacizumab","indication_name":"Metastatic renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avastin","generic_name":"bevacizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"Vascular Endothelial Growth Factor Inhibitor [EPC]","quality_score":82,"revenue":"2100","mechanism":"Bevacizumab works by binding to VEGF-A, preventing it from promoting the growth of new blood vessels that feed tumors."},{"drug_id":"cemiplimab","indication_name":"Metastatic basal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Libtayo","generic_name":"CEMIPLIMAB","company_name":"Regeneron Pharmaceuticals ","drug_phase":"marketed","molecular_target":"PD-1","drug_class":"","quality_score":64,"revenue":"1452","mechanism":"Cemiplimab-rwlc binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, enhancing the immune response against tumors."},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"nyvepria","indication_name":"Allogeneic peripheral blood stem cell transplant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neulasta","generic_name":"Pegfilgrastim-Apgf","company_name":"Amgen","drug_phase":"marketed","molecular_target":"G-CSF receptor on hematopoietic cells","drug_class":"Colony-stimulating factor","quality_score":10,"revenue":"1200","mechanism":"Colony-stimulating factor binding hematopoietic cell surface receptors to stimulate proliferation and differentiation."},{"drug_id":"lorbrena","indication_name":"ALK fusion gene-positive non-small-cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lorbrena","generic_name":"Lorlatinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":70,"revenue":"1100","mechanism":"Lorbrena works by blocking the activity of the ALK tyrosine kinase receptor, which is a protein that helps cancer cells grow."},{"drug_id":"lenvatinib","indication_name":"Hurthle cell carcinoma of thyroid","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lenvima","generic_name":"LENVATINIB","company_name":"Eisai","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase receptor Ret","drug_class":"Kinase Inhibitor [EPC]","quality_score":75,"revenue":"1053.0","mechanism":"Lenvima works by blocking the activity of a specific protein called Ret, which is involved in the growth and spread of cancer cells."},{"drug_id":"abrysvo","indication_name":"Prevention of rabies in individuals who have been bitten or otherwise exposed to rabies or have been at risk of rabies exposure and have been vaccinated with a cell culture vaccine or an inactivated rabies vaccine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrysvo","generic_name":"abrysvo","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"RSV","drug_class":"vaccine","quality_score":60,"revenue":"1033","mechanism":"ABRYSVO is a vaccine that protects against respiratory syncytial virus (RSV)."},{"drug_id":"cyclophosphamide","indication_name":"Treatment prior to tumor-specific T-cell infusion therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"cyclophosphamide","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Tumor cell DNA","drug_class":"Alkylating agent","quality_score":10,"revenue":"1000.0","mechanism":"Cyclophosphamide cross-links tumor cell DNA and interferes with malignant cell growth through active alkylating metabolites."},{"drug_id":"brentuximab-vedotin","indication_name":"Anaplastic large T-cell systemic malignant lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Adcetris","generic_name":"brentuximab-vedotin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tubulin beta","drug_class":"CD30-directed Immunoconjugate [EPC]","quality_score":10,"revenue":"900","mechanism":"Adcetris works by binding to cancer cells that express CD30 and delivering a toxic payload to kill the cells."},{"drug_id":"brentuximab-vedotin","indication_name":"Cutaneous Tcell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Adcetris","generic_name":"brentuximab-vedotin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tubulin beta","drug_class":"CD30-directed Immunoconjugate [EPC]","quality_score":10,"revenue":"900","mechanism":"Adcetris works by binding to cancer cells that express CD30 and delivering a toxic payload to kill the cells."},{"drug_id":"brentuximab-vedotin","indication_name":"CD30-positive peripheral T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Adcetris","generic_name":"brentuximab-vedotin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tubulin beta","drug_class":"CD30-directed Immunoconjugate [EPC]","quality_score":10,"revenue":"900","mechanism":"Adcetris works by binding to cancer cells that express CD30 and delivering a toxic payload to kill the cells."},{"drug_id":"tislelizumab","indication_name":"Unresectable or metastatic esophageal squamous cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tevimbra","generic_name":"TISLELIZUMAB","company_name":"Beigene","drug_phase":"marketed","molecular_target":"Pd-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"900","mechanism":"Tevimbra blocks the PD-1 receptor, allowing the immune system to recognize and attack cancer cells."},{"drug_id":"tislelizumab","indication_name":"Unresectable or metastatic esophageal squamous cell carcinoma (ESCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tevimbra","generic_name":"TISLELIZUMAB","company_name":"Beigene","drug_phase":"marketed","molecular_target":"Pd-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"900","mechanism":"Tevimbra blocks the PD-1 receptor, allowing the immune system to recognize and attack cancer cells."},{"drug_id":"amivantamab","indication_name":"Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rybrevant","generic_name":"AMIVANTAMAB","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"EGFR, MET","drug_class":"","quality_score":59,"revenue":"800","mechanism":"Amivantamab-vmjw targets EGFR and MET, disrupting their signaling and enhancing immune cell-mediated destruction of tumor cells."},{"drug_id":"lorlatinib-with-chemotherapy-2","indication_name":"Anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) with brain metastases","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lorlatinib with chemotherapy 2","generic_name":"lorlatinib-with-chemotherapy-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"ALK","drug_class":"ALK inhibitor","quality_score":40,"revenue":"798","mechanism":""},{"drug_id":"selpercatinib","indication_name":"Metastatic non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Retevmo","generic_name":"SELPERCATINIB","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase receptor Ret","drug_class":"Kinase Inhibitor [EPC]","quality_score":69,"revenue":"700","mechanism":"Retevmo works by blocking the activity of the RET protein, which is involved in the growth and spread of cancer cells."},{"drug_id":"selpercatinib","indication_name":"Advanced RET fusion-positive non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Retevmo","generic_name":"SELPERCATINIB","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase receptor Ret","drug_class":"Kinase Inhibitor [EPC]","quality_score":69,"revenue":"700","mechanism":"Retevmo works by blocking the activity of the RET protein, which is involved in the growth and spread of cancer cells."},{"drug_id":"alectinib","indication_name":"Anaplastic lymphoma kinase positive anaplastic large cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alecensa","generic_name":"alectinib","company_name":"Hoffmann-La Roche","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor","quality_score":79,"revenue":"700","mechanism":"Alecensa blocks the activity of the ALK protein, which is involved in the growth and spread of cancer cells."},{"drug_id":"everolimus","indication_name":"Subependymal Giant Cell Astrocytoma associated with Tuberous Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Afinitor","generic_name":"everolimus","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase mTOR","drug_class":"Kinase Inhibitor [EPC]","quality_score":67,"revenue":"600","mechanism":"Afinitor works by blocking the mTOR protein, which is involved in cell growth and division."},{"drug_id":"tremelimumab","indication_name":"Metastatic non-small cell lung cancer with no anaplastic lymphoma kinase genomic tumor aberrations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imjudo","generic_name":"TREMELIMUMAB","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"CTLA-4","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":62,"revenue":"400","mechanism":"Tremelimumab-actl binds to CTLA-4, blocking its interaction with CD80 and CD86, thereby enhancing T-cell activation and reducing tumor growth."},{"drug_id":"sotorasib","indication_name":"KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lumakras","generic_name":"SOTORASIB","company_name":"Amgen","drug_phase":"marketed","molecular_target":"GTPase KRas","drug_class":"","quality_score":65,"revenue":"300","mechanism":"Lumakras works by covalently binding to the KRAS G12C mutation, thereby blocking the protein's ability to promote cancer cell growth."},{"drug_id":"mogamulizumab","indication_name":"Peripheral T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Poteligeo","generic_name":"MOGAMULIZUMAB","company_name":"Kyowa Kirin","drug_phase":"marketed","molecular_target":"C-C chemokine receptor type 4","drug_class":"Chemokine Receptor Type 4 Interaction [EPC]","quality_score":10,"revenue":"300","mechanism":"Poteligeo works by binding to the C-C chemokine receptor type 4, which is involved in the migration and proliferation of T-cells."},{"drug_id":"glofitamab","indication_name":"Relapsed or refractory diffuse large B-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Columvi","generic_name":"glofitamab","company_name":"Roche","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"Bispecific CD20-directed CD3 T Cell Engager [EPC]","quality_score":79,"revenue":"300","mechanism":"Columvi works by binding to the CD20 protein on B-cell lymphoma cells, triggering an immune response to destroy the cancer cells."},{"drug_id":"entrectinib","indication_name":"Reactive oxygen species 1 positive non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rozlytrek","generic_name":"entrectinib","company_name":"Roche","drug_phase":"marketed","molecular_target":"High affinity nerve growth factor receptor","drug_class":"","quality_score":59,"revenue":"300","mechanism":"Rozlytrek works by blocking the activity of a specific protein called the nerve growth factor receptor."},{"drug_id":"mogamulizumab","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Poteligeo","generic_name":"MOGAMULIZUMAB","company_name":"Kyowa Kirin","drug_phase":"marketed","molecular_target":"C-C chemokine receptor type 4","drug_class":"Chemokine Receptor Type 4 Interaction [EPC]","quality_score":10,"revenue":"300","mechanism":"Poteligeo works by binding to the C-C chemokine receptor type 4, which is involved in the migration and proliferation of T-cells."},{"drug_id":"oxbryta","indication_name":"Treatment of sickle cell disease (SCD) in pediatric patients 4 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oxbryta","generic_name":"Voxelotor","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Hemoglobin S (HbS)","drug_class":"Hemoglobin S polymerization inhibitor","quality_score":10,"revenue":"250","mechanism":"Hemoglobin S polymerization inhibitor that binds HbS 1:1 and increases oxygen affinity."},{"drug_id":"oxbryta","indication_name":"Treatment of sickle cell disease (SCD) in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oxbryta","generic_name":"Voxelotor","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Hemoglobin S (HbS)","drug_class":"Hemoglobin S polymerization inhibitor","quality_score":10,"revenue":"250","mechanism":"Hemoglobin S polymerization inhibitor that binds HbS 1:1 and increases oxygen affinity."},{"drug_id":"adagrasib","indication_name":"KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Krazati","generic_name":"ADAGRASIB","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"GTPase KRas","drug_class":"","quality_score":66,"revenue":"205","mechanism":"Krazati works by binding to and inhibiting the GTPase activity of the KRAS G12C protein, preventing it from sending signals that promote cancer cell growth."},{"drug_id":"inotuzumab","indication_name":"Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in pediatric patients 1 year and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Besponsa","generic_name":"inotuzumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD22","drug_class":"CD22-directed Immunoconjugate [EPC]","quality_score":68,"revenue":"200","mechanism":"Inotuzumab ozogamicin is a CD22-directed antibody drug conjugate that targets and kills cancer cells."},{"drug_id":"midostaurin","indication_name":"Mast cell leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rydapt","generic_name":"MIDOSTAURIN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Mast/stem cell growth factor receptor Kit","drug_class":"Kinase Inhibitor [EPC]","quality_score":62,"revenue":"200","mechanism":"Rydapt blocks the activity of the Kit receptor, which is involved in the growth and survival of cancer cells."},{"drug_id":"inotuzumab","indication_name":"Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Besponsa","generic_name":"inotuzumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD22","drug_class":"CD22-directed Immunoconjugate [EPC]","quality_score":68,"revenue":"200","mechanism":"Inotuzumab ozogamicin is a CD22-directed antibody drug conjugate that targets and kills cancer cells."},{"drug_id":"besponsa","indication_name":"Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Besponsa","generic_name":"Inotuzumab Ozogamicin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"CD22","drug_class":"Antibody-drug conjugate (ADC)","quality_score":10,"revenue":"200","mechanism":"CD22-directed antibody-drug conjugate delivering cytotoxic calicheamicin to induce DNA breaks and apoptosis."},{"drug_id":"besponsa","indication_name":"Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in pediatric patients 1 year and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Besponsa","generic_name":"Inotuzumab Ozogamicin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"CD22","drug_class":"Antibody-drug conjugate (ADC)","quality_score":10,"revenue":"200","mechanism":"CD22-directed antibody-drug conjugate delivering cytotoxic calicheamicin to induce DNA breaks and apoptosis."},{"drug_id":"capmatinib","indication_name":"Metastatic non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tabrecta","generic_name":"CAPMATINIB","company_name":"Novartis Pharm","drug_phase":"marketed","molecular_target":"Hepatocyte growth factor receptor","drug_class":"Kinase Inhibitor","quality_score":66,"revenue":"200","mechanism":"Tabrecta works by blocking the hepatocyte growth factor receptor, a protein that helps cancer cells grow and spread."},{"drug_id":"repotrectinib","indication_name":"Locally advanced or metastatic ROS1-positive non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Augtyro","generic_name":"REPOTRECTINIB","company_name":"Bristol","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":60,"revenue":"200","mechanism":"Augtyro blocks the activity of ROS1 and NTRK kinases, which are abnormal proteins that help cancer cells grow and spread."},{"drug_id":"chembl-chembl2108611","indication_name":"Relapsed or Refractory CD22+ B-cell Precursor ALL","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"INOTUZUMAB OZOGAMICIN","company_name":"","drug_phase":"marketed","molecular_target":"CD22","drug_class":"CD22-directed Immunoconjugate [EPC]","quality_score":61,"revenue":"200","mechanism":"Inotuzumab ozogamicin is a CD22-directed antibody-drug conjugate that binds to CD22 on tumor cells, internalizes, and releases a cytotoxic agent causing DNA damage and cell death."},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tafasitamab","indication_name":"Malignant lymphoma, large B-cell, diffuse","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xmab5574","generic_name":"tafasitamab","company_name":"Morphosys Us Inc","drug_phase":"discontinued","molecular_target":"B-lymphocyte antigen CD19","drug_class":"","quality_score":null,"revenue":"100","mechanism":"Tafasitamab works by binding to the CD19 antigen on B-lymphocytes, triggering an immune response against cancer cells."},{"drug_id":"fluticasone-propionate","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cutivate","generic_name":"FLUTICASONE PROPIONATE","company_name":"Teva Pharm","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":64,"revenue":"69.0","mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Cutaneous T-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Peripheral T-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory T-Cell Large Granular Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Mantle Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Diffuse Large B-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"cromoglicic-acid","indication_name":"Systemic mast cell disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Intal","generic_name":"cromoglicic acid","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"G-protein coupled receptor 35","drug_class":"Mast Cell Stabilizer","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"zirabev","indication_name":"Metastatic renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bevacizumab","generic_name":"Bevacizumab-Bvzr","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular Endothelial Growth Factor (VEGF)","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":"Bevacizumab binds VEGF and prevents interaction with endothelial cell receptors Flt-1 and KDR."},{"drug_id":"dexamethasone","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"fluticasone","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Flonase","generic_name":"fluticasone propionate","company_name":"GSK (GlaxoSmithKline)","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Inhaled/intranasal corticosteroid","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"piperacillin","indication_name":"Bacteroides Pelvic Cellulitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pipracil","generic_name":"PIPERACILLIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"piperacillin","quality_score":10,"revenue":null,"mechanism":"Pipracil works by inhibiting bacterial cell wall synthesis, ultimately leading to cell lysis and death."},{"drug_id":"piperacillin","indication_name":"Enterococcus Pelvic Cellulitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pipracil","generic_name":"PIPERACILLIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"piperacillin","quality_score":10,"revenue":null,"mechanism":"Pipracil works by inhibiting bacterial cell wall synthesis, ultimately leading to cell lysis and death."},{"drug_id":"brentuximab","indication_name":"Anaplastic large T-cell systemic malignant lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Brentuximab","company_name":"University of Arizona","drug_phase":"discontinued","molecular_target":"Tumor necrosis factor receptor superfamily member 8, Tubulin beta","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"brentuximab","indication_name":"CD30-positive peripheral T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Brentuximab","company_name":"University of Arizona","drug_phase":"discontinued","molecular_target":"Tumor necrosis factor receptor superfamily member 8, Tubulin beta","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"brentuximab","indication_name":"Cutaneous Tcell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Brentuximab","company_name":"University of Arizona","drug_phase":"discontinued","molecular_target":"Tumor necrosis factor receptor superfamily member 8, Tubulin beta","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"cromoglicate","indication_name":"Systemic mast cell disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cromoglicate","company_name":"LEO Pharma","drug_phase":"discontinued","molecular_target":"Protein S100-P, G-protein coupled receptor 35, Taste receptor type 2 member 20","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"allr3","indication_name":"Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Allr3","generic_name":"allr3","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"The molecular target of ALLR3 is not specified.","drug_class":"The pharmacological class of ALLR3 is not specified.","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"allr3","indication_name":"Relapsed or refractory mantle cell lymphoma (MCL) after at least two prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Allr3","generic_name":"allr3","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"The molecular target of ALLR3 is not specified.","drug_class":"The pharmacological class of ALLR3 is not specified.","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"lorlatinib","indication_name":"ALK fusion gene-positive non-small-cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lorbrena","generic_name":"lorlatinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Lorbrena works by blocking the activity of the ALK tyrosine kinase receptor, which is a protein that helps cancer cells grow."},{"drug_id":"tagraxofusp","indication_name":"Blastic plasmacytoid dendritic cell neoplasm","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Molecule 129","generic_name":"TAGRAXOFUSP","company_name":"Stemline Therapeeutics Inc","drug_phase":"marketed","molecular_target":"Elongation factor 2","drug_class":"CD123 Interaction [EPC]","quality_score":10,"revenue":null,"mechanism":"Tagraxofusp works by binding to CD123 on cancer cells, causing them to die."},{"drug_id":"doxorubicin-hydrochloride","indication_name":"Metastatic transitional cell bladder carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Doxorubicin Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, nucleotide bases","drug_class":"Anthracycline topoisomerase inhibitor","quality_score":70,"revenue":null,"mechanism":"Doxorubicin intercalates nucleotide bases and interacts with topoisomerase II to form DNA-cleavable complexes, inhibiting DNA/RNA replication."},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"First-line treatment of patients with squamous cell carcinoma of the head and neck (SCCHN) in combination with 5-fluorouracil and radiation therapy.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) in combination with 5-fluorouracil.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"farydak","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Farydak","company_name":"Novartis Pharmaceuticals","drug_phase":"discontinued","molecular_target":"Bromodomain-containing protein 4, Histone deacetylase 1, Histone deacetylase 10","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"15-valent-pneumococcal-conjugate-vaccine-pcv15","indication_name":"Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with sickle cell disease.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"15-valent pneumococcal conjugate vaccine (PCV15)","generic_name":"15-valent-pneumococcal-conjugate-vaccine-pcv15","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folotyn","indication_name":"Peripheral T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Folotyn","company_name":"Acrotech Biopharma Inc.","drug_phase":"discontinued","molecular_target":"Folate transporter 1, Proton-coupled folate transporter, Dihydrofolate reductase","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic non-small cell lung cancer with an activating EGFR mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic non-small cell lung cancer with a tumor harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"advanced-therapy-only-without-dietary-intervention","indication_name":"Autologous Stem Cell Transplantation for the Treatment of HIV","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Advanced therapy only without dietary intervention","generic_name":"advanced-therapy-only-without-dietary-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various cell types","drug_class":"advanced therapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"advanced-therapy-only-without-dietary-intervention","indication_name":"Bone Marrow-Derived Mesenchymal Stem Cells for the Treatment of Graft-Versus-Host Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Advanced therapy only without dietary intervention","generic_name":"advanced-therapy-only-without-dietary-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various cell types","drug_class":"advanced therapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"advanced-therapy-only-without-dietary-intervention","indication_name":"Bone Marrow-Derived Mesenchymal Stem Cells for the Treatment of Sickle Cell Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Advanced therapy only without dietary intervention","generic_name":"advanced-therapy-only-without-dietary-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various cell types","drug_class":"advanced therapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"advanced-therapy-only-without-dietary-intervention","indication_name":"Bone Marrow-Derived Mesenchymal Stem Cells for the Treatment of Systemic Lupus Erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Advanced therapy only without dietary intervention","generic_name":"advanced-therapy-only-without-dietary-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various cell types","drug_class":"advanced therapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"advanced-therapy-only-without-dietary-intervention","indication_name":"Bone Marrow-Derived Mesenchymal Stem Cells for the Treatment of Type 1 Diabetes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Advanced therapy only without dietary intervention","generic_name":"advanced-therapy-only-without-dietary-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various cell types","drug_class":"advanced therapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"advanced-therapy-only-without-dietary-intervention","indication_name":"Bone Marrow-Derived Mesenchymal Stem Cells for the Treatment of Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Advanced therapy only without dietary intervention","generic_name":"advanced-therapy-only-without-dietary-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various cell types","drug_class":"advanced therapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"gleevec","indication_name":"Systemic mast cell disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Gleevec","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, ATP-binding cassette sub-family G member 2, ATP-dependent RNA helicase DDX3X","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"campath","indication_name":"Conditioning treatment prior to allogeneic haematopoietic stem cell transplant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Campath","company_name":"National Heart, Lung, and Blood Institute (NHLBI)","drug_phase":"marketed","molecular_target":"CAMPATH-1 antigen","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"pembrolizuma","indication_name":"Metastatic renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pembrolizuma","company_name":"Memorial Sloan Kettering Cancer Center","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"","quality_score":14,"revenue":null,"mechanism":null},{"drug_id":"cabozantinib","indication_name":"Metastatic renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cometriq","generic_name":"CABOZANTINIB","company_name":"Exelixis Inc","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor receptor 2","drug_class":"Kinase Inhibitor","quality_score":53,"revenue":null,"mechanism":"Cometriq works by blocking the activity of vascular endothelial growth factor receptor 2, a protein involved in tumor growth and angiogenesis."},{"drug_id":"afinitor","indication_name":"Subependymal Giant Cell Astrocytoma associated with Tuberous Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Afinitor","company_name":"Central European Society for Anticancer Drug Research","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1, Peptidyl-prolyl cis-trans isomerase FKBP1A, Serine/threonine-protein kinase mTOR","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"cyclophosphamid","indication_name":"Treatment prior to tumor-specific T-cell infusion therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cyclophosphamid","company_name":"Zhejiang University","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"zenocutuzumab","indication_name":"advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bizengri","generic_name":"ZENOCUTUZUMAB","company_name":"Merus N.V.","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Bizengri works by binding to a specific protein on cancer cells to block their growth and spread."},{"drug_id":"yervoy","indication_name":"Metastatic nonsmall cell lung cancer with no sensitising EGFR mutation or ALK translocation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Yervoy","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"imfinzi","indication_name":"Extensive stage primary small cell carcinoma of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Imfinzi","company_name":"University Medical Center Groningen","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"imfinzi","indication_name":"Transitional cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Imfinzi","company_name":"University Medical Center Groningen","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"istodax","indication_name":"Peripheral T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Istodax","company_name":"Celgene","drug_phase":"marketed","molecular_target":"Bromodomain-containing protein 4, Histone deacetylase 3/NCoR1, Histone deacetylase 3/Nuclear receptor corepressor 2 (HDAC3/NCoR2)","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"istodax","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Istodax","company_name":"Celgene","drug_phase":"marketed","molecular_target":"Bromodomain-containing protein 4, Histone deacetylase 3/NCoR1, Histone deacetylase 3/Nuclear receptor corepressor 2 (HDAC3/NCoR2)","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"poteligeo","indication_name":"Peripheral T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Poteligeo","company_name":"Kyowa Kirin Pharmaceutical Development Ltd","drug_phase":"marketed","molecular_target":"C-C chemokine receptor type 4","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"poteligeo","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Poteligeo","company_name":"Kyowa Kirin Pharmaceutical Development Ltd","drug_phase":"marketed","molecular_target":"C-C chemokine receptor type 4","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"prednison","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednison","company_name":"Wen Zhang","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"velcade","indication_name":"Mantle cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Velcade","company_name":"University of Arkansas","drug_phase":"marketed","molecular_target":"26S proteasome non-ATPase regulatory subunit 1, PH and SEC7 domain-containing protein 1, Cathepsin G","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"pediarix","indication_name":"Protection against diphtheria, tetanus, pertussis (whole-cell), hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b (Hib) disease in infants and children from 6 weeks through 6 years of age.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pediarix","generic_name":"pediarix","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Immune system","drug_class":"vaccine","quality_score":37,"revenue":null,"mechanism":""},{"drug_id":"pediarix","indication_name":"Protection against diphtheria, tetanus, pertussis (whole-cell), hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b (Hib) disease in infants and children from 6 weeks through 6 years of age, when used in a 3-dose series.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pediarix","generic_name":"pediarix","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Immune system","drug_class":"vaccine","quality_score":37,"revenue":null,"mechanism":""},{"drug_id":"pegfilgrastim-jmdb","indication_name":"Allogeneic peripheral blood stem cell transplant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"FULPHILA","generic_name":"PEGFILGRASTIM-JMDB","company_name":"MYLAN GMBH","drug_phase":"marketed","molecular_target":"Granulocyte colony-stimulating factor receptor","drug_class":"Leukocyte Growth Factor [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafasitamab-cxix","indication_name":"Malignant lymphoma, large B-cell, diffuse","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MONJUVI","generic_name":"TAFASITAMAB-CXIX","company_name":"MORPHOSYS US INC","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD19","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"nasonex","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nasonex","company_name":"University of Alberta","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1, Glucocorticoid receptor, Progesterone receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"amivantamab-vmjw","indication_name":"Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"RYBREVANT","generic_name":"AMIVANTAMAB-VMJW","company_name":"JANSSEN BIOTECH","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor, Hepatocyte growth factor receptor","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"relatlimab-rmbw","indication_name":"Advanced melanoma with tumour cell PD-L1 expression below 1%","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"OPDUALAG","generic_name":"RELATLIMAB-RMBW","company_name":"BRISTOL MYERS SQUIBB","drug_phase":"marketed","molecular_target":"Lymphocyte activation gene 3 protein","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tremelimumab-actl","indication_name":"Metastatic non-small cell lung cancer with no anaplastic lymphoma kinase genomic tumor aberrations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"IMJUDO","generic_name":"TREMELIMUMAB-ACTL","company_name":"ASTRAZENECA AB","drug_phase":"marketed","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"glofitamab-gxbm","indication_name":"Relapsed or refractory diffuse large B-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"COLUMVI","generic_name":"GLOFITAMAB-GXBM","company_name":"GENENTECH INC","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20, T-cell surface glycoprotein CD3 epsilon chain","drug_class":"Bispecific CD20-directed CD3 T Cell Engager [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"methylprednisolone","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrol","generic_name":"methylprednisolone","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"Glucocorticoid (corticosteroid)","quality_score":62,"revenue":null,"mechanism":"Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions."},{"drug_id":"betamethasone-benzoate","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betamethasone 17-Benzoate","generic_name":"BETAMETHASONE BENZOATE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Anaplastic Large Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Blastoid Mantle Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Spindle Cell Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Spindle Cell Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Spindle Cell Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Spindle Cell Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Spindle Cell Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Spindle Cell Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Spindle Cell Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Spindle Cell Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Spindle Cell Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Spindle Cell Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Spindle Cell Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Spindle Cell Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Spindle Cell Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Spindle Cell Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Spindle Cell Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"dacomitinib-hydrate","indication_name":"EGFR mutation-positive, unresectable or recurrent non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"dacomitinib hydrate","generic_name":"dacomitinib-hydrate","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"Cyclin-G-associated kinase, Receptor-interacting serine/threonine-protein kinase 2, Receptor-interacting serine/threonine-protein kinase 3","drug_class":"The usual adult starting dosage for oral use is 45mg of dacomitinib hydrate once daily. The dose sho","quality_score":null,"revenue":null,"mechanism":"The usual adult starting dosage for oral use is 45mg of dacomitinib hydrate once daily. The dose sho"},{"drug_id":"part-c-met097","indication_name":"Treatment of Mast Cell Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"(Part C) MET097","generic_name":"part-c-met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":37,"revenue":null,"mechanism":"The exact mechanism of action is not specified on Wikipedia."},{"drug_id":"part-c-met097","indication_name":"Treatment of Mast Cell Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"(Part C) MET097","generic_name":"part-c-met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":37,"revenue":null,"mechanism":"The exact mechanism of action is not specified on Wikipedia."},{"drug_id":"part-c-met097","indication_name":"Treatment of Mast Cell Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"(Part C) MET097","generic_name":"part-c-met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":37,"revenue":null,"mechanism":"The exact mechanism of action is not specified on Wikipedia."},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of hepatocellular carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of mast cell leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of mantle cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of diffuse large B-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of peripheral T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of anaplastic large cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of angioimmunoblastic T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of adult T-cell leukemia/lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of mantle cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of diffuse large B-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of peripheral T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of anaplastic large cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of angioimmunoblastic T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of adult T-cell leukemia/lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of mantle cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of diffuse large B-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of peripheral T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of anaplastic large cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of angioimmunoblastic T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of adult T-cell leukemia/lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of mantle cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of diffuse large B-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of peripheral T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of anaplastic large cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of angioimmunoblastic T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of adult T-cell leukemia/lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of mantle cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of diffuse large B-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of peripheral T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of anaplastic large cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of angioimmunoblastic T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of adult T-cell leukemia/lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of mantle cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of diffuse large B-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of peripheral T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of anaplastic large cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of angioimmunoblastic T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of adult T-cell leukemia/lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of mantle cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of diffuse large B-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of peripheral T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of anaplastic large cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of angioimmunoblastic T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of adult T-cell leukemia/lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of mantle cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of diffuse large B-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of peripheral T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of anaplastic large cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of angioimmunoblastic T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of adult T-cell leukemia/lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of mantle cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of diffuse large B-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"bortezomib","indication_name":"Mantle cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Velcade","generic_name":"bortezomib","company_name":"Shilpa","drug_phase":"marketed","molecular_target":"26S proteasome chymotrypsin-like activity","drug_class":"Proteasome inhibitor","quality_score":76,"revenue":null,"mechanism":"Reversible inhibitor of 26S proteasome chymotrypsin-like activity preventing ubiquitinated protein degradation."},{"drug_id":"loncastuximab","indication_name":"relapsed or refractory large B-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zynlonta","generic_name":"LONCASTUXIMAB","company_name":"ADC Therapeutics SA","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":47,"revenue":null,"mechanism":"Zynlonta works by binding to a specific target on cancer cells, marking them for destruction."},{"drug_id":"busilvex","indication_name":"Autologous hematopoietic stem-cell transplantation for Ewing's sarcoma family of tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Busilvex","company_name":"medac GmbH","drug_phase":"phase_2","molecular_target":"Matrix metalloproteinase-9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"romidepsin","indication_name":"Peripheral T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Istodax","generic_name":"ROMIDEPSIN","company_name":"Teva Pharms Usa Inc","drug_phase":"marketed","molecular_target":"HDACs","drug_class":"Histone Deacetylase Inhibitor","quality_score":62,"revenue":null,"mechanism":"Romidepsin inhibits HDACs, leading to increased acetylation of histones and non-histone proteins, causing cell cycle arrest and apoptosis in cancer cells."},{"drug_id":"romidepsin","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Istodax","generic_name":"ROMIDEPSIN","company_name":"Teva Pharms Usa Inc","drug_phase":"marketed","molecular_target":"HDACs","drug_class":"Histone Deacetylase Inhibitor","quality_score":62,"revenue":null,"mechanism":"Romidepsin inhibits HDACs, leading to increased acetylation of histones and non-histone proteins, causing cell cycle arrest and apoptosis in cancer cells."},{"drug_id":"triamcinolone","indication_name":"Giant cell arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"triamcinolone","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"flixotide","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Flixotide","company_name":"Mundipharma Research Limited","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"fluticason","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fluticason","company_name":"Creighton University","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"imbruvica","indication_name":"Mantle cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Imbruvica","company_name":"Rabin Medical Center","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 4 group A member 3, Platelet glycoprotein VI, Serine/threonine-protein kinase LATS1","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"mozobil","indication_name":"Peripheral Mobilization of Hematopoietic Stem Cells","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mozobil","company_name":"University of Washington","drug_phase":"marketed","molecular_target":"Stromal cell-derived factor 1, Atypical chemokine receptor 3, C-C chemokine receptor type 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"calquence","indication_name":"Mantle cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Calquence","company_name":"iOMEDICO AG","drug_phase":"marketed","molecular_target":"Platelet glycoprotein VI, Cytoplasmic tyrosine-protein kinase BMX, Tyrosine-protein kinase Blk","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"chidamide","indication_name":"Peripheral T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Chidamide","company_name":"Sun Yat-sen University","drug_phase":"phase_3","molecular_target":"Nicotinamide phosphoribosyltransferase, Histone deacetylase 1, Histone deacetylase 10","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"chidamide","indication_name":"Relapsed or refractory T-cell leukemia-lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Chidamide","company_name":"Sun Yat-sen University","drug_phase":"phase_3","molecular_target":"Nicotinamide phosphoribosyltransferase, Histone deacetylase 1, Histone deacetylase 10","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisone","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"vizimpro","indication_name":"EGFR mutation-positive, unresectable or recurrent non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vizimpro","generic_name":"Dacomitinib","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cyclin-G-associated kinase, Receptor-interacting serine/threonine-protein kinase 2, Receptor-interacting serine/threonine-protein kinase 3","drug_class":"Tyrosine kinase inhibitor (TKI); Pan-HER inhibitor","quality_score":75,"revenue":null,"mechanism":"Irreversible pan-HER kinase inhibitor targeting EGFR, HER2, HER4, and EGFR-activating mutations."},{"drug_id":"aciphex","indication_name":"Systemic mast cell disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Aciphex","company_name":"University of Utah","drug_phase":"marketed","molecular_target":"Sterile alpha and TIR motif-containing protein 1, ATP-binding cassette sub-family G member 2, Adenosine receptor A3","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"epcoritamab","indication_name":"Relapsed or refractory diffuse large B-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epkinly","generic_name":"EPCORITAMAB","company_name":"Genmab Us, Inc.","drug_phase":"marketed","molecular_target":"T-cell surface glycoprotein CD3","drug_class":"Bispecific CD20-directed CD3 T Cell Engager [EPC]","quality_score":10,"revenue":null,"mechanism":"Epkinly works by binding to the T-cell surface glycoprotein CD3, which is a key component of the T-cell receptor complex."},{"drug_id":"mesna","indication_name":"Testicular Germ Cell Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mesnex","generic_name":"MESNA","company_name":"Baxter","drug_phase":"marketed","molecular_target":"","drug_class":"mesna","quality_score":70,"revenue":null,"mechanism":"Mesnex works by binding to and neutralizing acrolein, a toxic byproduct of chemotherapy that causes hemorrhagic cystitis."},{"drug_id":"zongertinib","indication_name":"unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hernexeos","generic_name":"ZONGERTINIB","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Hernexeos works by blocking the HER2 tyrosine kinase domain, which is a protein that helps cancer cells grow and divide."},{"drug_id":"zongertinib","indication_name":"unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hernexeos","generic_name":"ZONGERTINIB","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Hernexeos works by blocking the HER2 tyrosine kinase domain, which is a protein that helps cancer cells grow and divide."},{"drug_id":"mycophenolate-mofetil","indication_name":"The suppression of graft-versus-host disease in hematopoietic stem cell transplantation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cellcept","generic_name":"MYCOPHENOLATE MOFETIL","company_name":"Roche Palo","drug_phase":"marketed","molecular_target":"Inosine-5'-monophosphate dehydrogenase 2","drug_class":"Antimetabolite Immunosuppressant","quality_score":10,"revenue":null,"mechanism":"Cellcept works by inhibiting the enzyme inosine-5'-monophosphate dehydrogenase 2, which is necessary for the production of guanosine nucleotides."},{"drug_id":"fluocinonide","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lidex","generic_name":"FLUOCINONIDE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cimetidine","indication_name":"Systemic mast cell disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tagamet","generic_name":"CIMETIDINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H2 receptor","drug_class":"Histamine-2 Receptor Antagonist [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"diazoxide","indication_name":"Islet cell hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Proglycem","generic_name":"DIAZOXIDE","company_name":"","drug_phase":"marketed","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"diazoxide","quality_score":55,"revenue":null,"mechanism":"Proglycem works by blocking the ATP-sensitive potassium channel, which helps to increase blood sugar levels and reduce insulin secretion."},{"drug_id":"cefoxitin","indication_name":"Bacteroides Pelvic Cellulitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mefoxin In Sodium Chloride 0.9% In Plastic Container","generic_name":"CEFOXITIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cefoxitin","indication_name":"Clostridium Pelvic Cellulitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mefoxin In Sodium Chloride 0.9% In Plastic Container","generic_name":"CEFOXITIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cefoxitin","indication_name":"Peptococcus Pelvic Cellulitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mefoxin In Sodium Chloride 0.9% In Plastic Container","generic_name":"CEFOXITIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cefoxitin","indication_name":"Peptostreptococcus Pelvic Cellulitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mefoxin In Sodium Chloride 0.9% In Plastic Container","generic_name":"CEFOXITIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"nipent","indication_name":"Untreated hairy cell leukemia with active disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nipent","generic_name":"Pentostatin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Adenosine deaminase (ADA)","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"nipent","indication_name":"Alpha-interferon-refractory hairy cell leukemia with active disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nipent","generic_name":"Pentostatin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Adenosine deaminase (ADA)","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"belinostat","indication_name":"Peripheral T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Beleodaq","generic_name":"belinostat","company_name":"Acrotech Biopharma","drug_phase":"marketed","molecular_target":"Histone deacetylase 1","drug_class":"Histone Deacetylase Inhibitor [EPC]","quality_score":65,"revenue":null,"mechanism":"Beleodaq works by blocking the enzyme that removes acetyl groups from histones, altering gene expression."},{"drug_id":"halcinonide","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Halog","generic_name":"HALCINONIDE","company_name":"Sun Pharma","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"rabeprazole","indication_name":"Systemic mast cell disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aciphex","generic_name":"rabeprazole","company_name":"Waylis","drug_phase":"marketed","molecular_target":"Potassium-transporting ATPase","drug_class":"Proton Pump Inhibitor","quality_score":80,"revenue":null,"mechanism":"Aciphex works by irreversibly inhibiting the potassium-transporting ATPase enzyme in the stomach lining, reducing acid production."},{"drug_id":"inavolisib","indication_name":"Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior lines of therapy for whom MAb-based therapy has failed","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Itovebi","generic_name":"inavolisib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"phosphatidylinositol 3-kinase (PI3K) alpha (PIK3CA)","drug_class":"Kinase Inhibitor [EPC]","quality_score":80,"revenue":null,"mechanism":"Inavolisib is a PI3K inhibitor with degradative activity against PI3Kα."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation in newly diagnosed patients who are eligible for autologous stem cell transplant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma in combination with bortezomib, lenalidomide, and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"imatinib","indication_name":"Systemic mast cell disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gleevec","generic_name":"imatinib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"Kinase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Gleevec works by blocking the activity of specific enzymes involved in cancer cell growth and proliferation."},{"drug_id":"pegfilgrastim","indication_name":"Allogeneic peripheral blood stem cell transplant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neulasta","generic_name":"PEGFILGRASTIM","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Granulocyte colony-stimulating factor receptor","drug_class":"Leukocyte Growth Factor [EPC]","quality_score":70,"revenue":null,"mechanism":"Neulasta stimulates the production of white blood cells by binding to their receptors."},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"tocilizumab","indication_name":"Giant Cell Arteritis (GCA)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Roactemra","generic_name":"tocilizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Interleukin-6 receptor","drug_class":"Interleukin-6 Receptor Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":"Roactemra works by blocking the interleukin-6 receptor, a protein that plays a key role in inflammation."},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"prednicarbate","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dermatop","generic_name":"PREDNICARBATE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tisagenlecleucel","indication_name":"relapsed or refractory (r/r) large B-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kymriah","generic_name":"TISAGENLECLEUCEL","company_name":"Novartis Pharmaceuticals Corporation","drug_phase":"marketed","molecular_target":"","drug_class":"CD19-directed Chimeric Antigen Receptor [EPC]","quality_score":50,"revenue":null,"mechanism":"Kymriah modifies a patient's T-cells to recognize and attack cancer cells expressing the CD19 protein."},{"drug_id":"tisagenlecleucel","indication_name":"relapsed or refractory (r/r) large B-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kymriah","generic_name":"TISAGENLECLEUCEL","company_name":"Novartis Pharmaceuticals Corporation","drug_phase":"marketed","molecular_target":"","drug_class":"CD19-directed Chimeric Antigen Receptor [EPC]","quality_score":50,"revenue":null,"mechanism":"Kymriah modifies a patient's T-cells to recognize and attack cancer cells expressing the CD19 protein."},{"drug_id":"avapritinib","indication_name":"Systemic mast cell disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ayvakit","generic_name":"AVAPRITINIB","company_name":"Blueprint Medicines","drug_phase":"marketed","molecular_target":"Platelet-derived growth factor receptor alpha","drug_class":"Kinase Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Ayvakit works by blocking the activity of the PDGFRA protein, which is involved in the growth and spread of cancer cells."},{"drug_id":"vimseltinib","indication_name":"symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Romvimza","generic_name":"VIMSELTINIB","company_name":"Deciphera Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Romvimza works by blocking a specific enzyme that helps cancer cells grow and survive."},{"drug_id":"taletrectinib","indication_name":"locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ibtrozi","generic_name":"TALETRECTINIB","company_name":"Nuvation","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Ibtrozi works by blocking the ROS1 protein, which is a genetic mutation found in some lung cancer cells."},{"drug_id":"ruxience","indication_name":"Burkitt cell leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"Rituximab-Pvvr","company_name":"Roche","drug_phase":"marketed","molecular_target":"CD20 antigen on pre-B and mature B-lymphocytes","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":"Monoclonal antibody targeting CD20 on B-lymphocytes, mediating cell lysis via CDC and ADCC."},{"drug_id":"ruxience","indication_name":"CD20 positive diffuse large B cell non Hodgkin's lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"Rituximab-Pvvr","company_name":"Roche","drug_phase":"marketed","molecular_target":"CD20 antigen on pre-B and mature B-lymphocytes","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":"Monoclonal antibody targeting CD20 on B-lymphocytes, mediating cell lysis via CDC and ADCC."},{"drug_id":"rituximab","indication_name":"Burkitt cell leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"rituximab","company_name":"Roche","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Mabthera works by binding to the CD20 antigen on B-lymphocytes, triggering their destruction."},{"drug_id":"rituximab","indication_name":"CD20 positive diffuse large B cell non Hodgkin's lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"rituximab","company_name":"Roche","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Mabthera works by binding to the CD20 antigen on B-lymphocytes, triggering their destruction."},{"drug_id":"e7777","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ontak","generic_name":"E7777","company_name":"Eisai","drug_phase":"marketed","molecular_target":"Interleukin-2 receptor","drug_class":"CD25-directed Cytotoxin","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"e7777","indication_name":"Refractory peripheral T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ontak","generic_name":"E7777","company_name":"Eisai","drug_phase":"marketed","molecular_target":"Interleukin-2 receptor","drug_class":"CD25-directed Cytotoxin","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tocilizumab","indication_name":"Cytokine release syndrome induced by tumor-specific T-cell infusion therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Roactemra","generic_name":"tocilizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Interleukin-6 receptor","drug_class":"Interleukin-6 Receptor Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":"Roactemra works by blocking the interleukin-6 receptor, a protein that plays a key role in inflammation."},{"drug_id":"tocilizumab","indication_name":"Giant cell arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Roactemra","generic_name":"tocilizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Interleukin-6 receptor","drug_class":"Interleukin-6 Receptor Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":"Roactemra works by blocking the interleukin-6 receptor, a protein that plays a key role in inflammation."},{"drug_id":"alemtuzumab","indication_name":"Conditioning treatment prior to allogeneic haematopoietic stem cell transplant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Campath","generic_name":"ALEMTUZUMAB","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"CAMPATH-1 antigen","drug_class":"CD52-directed Cytolytic Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Campath works by binding to a specific protein on the surface of immune cells, marking them for destruction."},{"drug_id":"aldesleukin","indication_name":"Metastatic renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Proleukin","generic_name":"ALDESLEUKIN","company_name":"Chiron","drug_phase":"marketed","molecular_target":"Interleukin-2 receptor","drug_class":"Lymphocyte Growth Factor [EPC]","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"disitamab-vedotin","indication_name":"Locally advanced or metastatic esophageal squamous cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Disitamab vedotin","generic_name":"disitamab-vedotin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"human epidermal growth factor receptor 2 (HER2)","drug_class":"antibody-drug conjugate","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"ppsv23","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae in adults 2 years of age or older with sickle cell disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ppsv23","generic_name":"ppsv23","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"denileukin-diftitox","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ontak","generic_name":"DENILEUKIN DIFTITOX","company_name":"Eisai","drug_phase":"marketed","molecular_target":"Interleukin-2 receptor","drug_class":"CD25-directed Cytotoxin [EPC]","quality_score":10,"revenue":null,"mechanism":"Ontak works by binding to the interleukin-2 receptor on cancer cells, triggering a toxic response that kills the cells."},{"drug_id":"denileukin-diftitox","indication_name":"Refractory peripheral T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ontak","generic_name":"DENILEUKIN DIFTITOX","company_name":"Eisai","drug_phase":"marketed","molecular_target":"Interleukin-2 receptor","drug_class":"CD25-directed Cytotoxin [EPC]","quality_score":10,"revenue":null,"mechanism":"Ontak works by binding to the interleukin-2 receptor on cancer cells, triggering a toxic response that kills the cells."},{"drug_id":"darinaparsin","indication_name":"Refractory peripheral T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darvias","generic_name":"DARINAPARSIN","company_name":"Solasia Pharma K.K","drug_phase":"discontinued","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Darvias works by inhibiting the enzyme glutathione S-transferase pi (GSTP1), which is involved in the cell's detoxification process."},{"drug_id":"mometasone-furoate","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elocon","generic_name":"MOMETASONE FUROATE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Progesterone receptor","drug_class":"Corticosteroid","quality_score":75,"revenue":null,"mechanism":"Elocon works by binding to the progesterone receptor, which reduces inflammation and immune response in the body."},{"drug_id":"89zr-zr-crefmirlimab-berdoxam","indication_name":"Plaquenil-resistant or -intolerant adult patients with cutaneous T-cell lymphoma (CTCL) who have had an inadequate response or are intolerant to at least one prior systemic therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"[89Zr]Zr-crefmirlimab berdoxam","generic_name":"89zr-zr-crefmirlimab-berdoxam","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Fibroblast Activation Protein (FAP)","drug_class":"Radiolabeled Monoclonal Antibody","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"anti-ox40-antibody-pf-04518600","indication_name":"Hepatocellular carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Anti-OX40 Antibody PF-04518600","generic_name":"anti-ox40-antibody-pf-04518600","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"OX40 receptor","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with sickle cell disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with sickle cell disease and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and sickle cell disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and HIV infection and sickle cell disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and sickle cell disease and cerebrospinal fluid leak","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and sickle cell disease and cochlear implant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"diflorasone-diacetate","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Psorcon","generic_name":"DIFLORASONE DIACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":39,"revenue":null,"mechanism":""},{"drug_id":"nelarabine","indication_name":"Precursor T-cell lymphoblastic lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arranon","generic_name":"NELARABINE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":75,"revenue":null,"mechanism":"Arranon works by inhibiting the enzyme responsible for converting nucleosides into their active forms, thereby preventing DNA synthesis in cancer cells."},{"drug_id":"nelarabine","indication_name":"T-cell acute lymphoblastic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arranon","generic_name":"NELARABINE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":75,"revenue":null,"mechanism":"Arranon works by inhibiting the enzyme responsible for converting nucleosides into their active forms, thereby preventing DNA synthesis in cancer cells."},{"drug_id":"methoxsalen","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oxsoralen-Ultra","generic_name":"METHOXSALEN","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Cytochrome P450 1A2","drug_class":"Photoactivated Radical Generator [EPC]","quality_score":65,"revenue":null,"mechanism":"Oxsoralen-Ultra works by generating free radicals when exposed to ultraviolet A (UVA) light, which helps to slow down the growth of skin cells and reduce inflammation."},{"drug_id":"dacomitinib","indication_name":"EGFR mutation-positive, unresectable or recurrent non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vizimpro","generic_name":"dacomitinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Vizimpro works by blocking the EGFR tyrosine kinase, a protein that helps cancer cells grow and survive."},{"drug_id":"trametinib","indication_name":"Metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mekinist","generic_name":"trametinib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Dual specificity mitogen-activated protein kinase kinase 2","drug_class":"Kinase Inhibitor","quality_score":71,"revenue":null,"mechanism":"Mekinist works by blocking a specific enzyme called BRAF V600E, which is involved in the growth and spread of cancer cells."},{"drug_id":"pralsetinib","indication_name":"Metastatic non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gavreto","generic_name":"PRALSETINIB","company_name":"Rigel Pharms","drug_phase":"marketed","molecular_target":"RET","drug_class":"Kinase Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Pralsetinib inhibits RET kinase and its oncogenic fusions/mutations, blocking downstream signaling and reducing tumor growth."},{"drug_id":"norfloxacin","indication_name":"Bacteroides Pelvic Cellulitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"norfloxacin","indication_name":"Enterococcus Pelvic Cellulitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"norfloxacin","indication_name":"Peptostreptococcus Pelvic Cellulitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"norfloxacin","indication_name":"Prevotella Pelvic Cellulitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"norfloxacin","indication_name":"Streptococcal Pelvic Cellulitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"amcinonide","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyclocort","generic_name":"AMCINONIDE","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"tolbutamide","indication_name":"Diagnostic Test for Pancreatic Islet Cell Adenoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aglicid","generic_name":"TOLBUTAMIDE","company_name":"","drug_phase":"marketed","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"Sulfonylurea","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"busulfan","indication_name":"Autologous hematopoietic stem-cell transplantation for Ewing's sarcoma family of tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Busulfex","generic_name":"busulfan","company_name":"Waylis","drug_phase":"marketed","molecular_target":"Matrix metalloproteinase-9","drug_class":"Alkylating Drug [EPC]","quality_score":10,"revenue":null,"mechanism":"Busulfex works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and ultimately leading to cell death."},{"drug_id":"betamethasone","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betametasone","generic_name":"BETAMETHASONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system."},{"drug_id":"treosulfan","indication_name":"Allogeneic peripheral blood stem cell transplant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trecondi","generic_name":"TREOSULFAN","company_name":"Medexus","drug_phase":"marketed","molecular_target":"","drug_class":"treosulfan","quality_score":48,"revenue":null,"mechanism":""},{"drug_id":"lorviqua","indication_name":"ALK fusion gene-positive non-small-cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lorviqua","generic_name":"lorviqua","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"Tyrosine-protein kinase FRK, ALK tyrosine kinase receptor, Activated CDC42 kinase 1","drug_class":"As provided in real world practice","quality_score":0,"revenue":null,"mechanism":"As provided in real world practice"},{"drug_id":"ifosfamide","indication_name":"Testicular Germ Cell Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ifex","generic_name":"IFOSFAMIDE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"","drug_class":"Alkylating Drug [EPC]","quality_score":70,"revenue":null,"mechanism":"Ifosfamide is activated by liver enzymes to form cytotoxic compounds that cause DNA crosslinks, leading to cell death."},{"drug_id":"carbamide","indication_name":"Metastatic non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"(CARBAMIDE®)","company_name":"German University in Cairo","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinase-like 5, Hepatocyte growth factor receptor","drug_class":"","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"vorinostat","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zolinza","generic_name":"VORINOSTAT","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Histone deacetylase 6","drug_class":"Histone Deacetylase Inhibitor [EPC]","quality_score":75,"revenue":null,"mechanism":"Zolinza works by blocking the action of histone deacetylase 6, an enzyme that removes acetyl groups from histones, leading to changes in gene expression."},{"drug_id":"chembl-chembl1200796","indication_name":"Treatment prior to tumor-specific T-cell infusion therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"CYCLOPHOSPHAMIDE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"cyclophosphamide","quality_score":10,"revenue":null,"mechanism":"Cytoxan works by interfering with the DNA replication process in rapidly dividing cancer cells."},{"drug_id":"ifo","indication_name":"Testicular Germ Cell Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IFO","company_name":"Italian Sarcoma Group","drug_phase":"marketed","molecular_target":"DNA","drug_class":"Alkylating Agent","quality_score":null,"revenue":null,"mechanism":"Ifosfamide is an alkylating agent that cross-links DNA, preventing cell replication and inducing apoptosis."},{"drug_id":"turalio","indication_name":"Tenosynovial giant cell tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TURALIO™","company_name":"Daiichi Sankyo","drug_phase":"marketed","molecular_target":"AP2-associated protein kinase 1, Aurora kinase B, Cyclin-dependent kinase 19","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Turalio works by inhibiting a specific biological pathway."},{"drug_id":"mogamulizumab-kpkc","indication_name":"Peripheral T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mogamulizumab-Kpkc","company_name":"H. Lee Moffitt Cancer Center and Research Institute","drug_phase":"discontinued","molecular_target":"C-C chemokine receptor type 4","drug_class":"Chemokine Receptor Type 4 Interaction [EPC]","quality_score":null,"revenue":null,"mechanism":"12.1 Mechanism of Action Mogamulizumab-kpkc is a defucosylated, humanized IgG1 kappa monoclonal antibody that binds to CCR4, a G protein-coupled receptor for CC chemokines that is involved in the trafficking of lymphocytes to various organs. Non-clinical in vitro studies demonstrate mogamulizumab-kpkc binding targets a cell for antibody-dependent cellular cytotoxicity (ADCC) resulting in depletion of the target cells. CCR4 is expressed on the surface of some T-cell malignancies and is expressed on regulatory T-cells (Treg) and a subset of Th2 T-cells."},{"drug_id":"mogamulizumab-kpkc","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mogamulizumab-Kpkc","company_name":"H. Lee Moffitt Cancer Center and Research Institute","drug_phase":"discontinued","molecular_target":"C-C chemokine receptor type 4","drug_class":"Chemokine Receptor Type 4 Interaction [EPC]","quality_score":null,"revenue":null,"mechanism":"12.1 Mechanism of Action Mogamulizumab-kpkc is a defucosylated, humanized IgG1 kappa monoclonal antibody that binds to CCR4, a G protein-coupled receptor for CC chemokines that is involved in the trafficking of lymphocytes to various organs. Non-clinical in vitro studies demonstrate mogamulizumab-kpkc binding targets a cell for antibody-dependent cellular cytotoxicity (ADCC) resulting in depletion of the target cells. CCR4 is expressed on the surface of some T-cell malignancies and is expressed on regulatory T-cells (Treg) and a subset of Th2 T-cells."},{"drug_id":"fludarabin","indication_name":"Mantle cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fludarabin","company_name":"Azienda Ospedaliera San Giovanni Battista","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 5A, mitochondrial, DNA polymerase alpha catalytic subunit, Ribonucleoside-diphosphate reductase large subunit","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cortisol","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"opdualag","indication_name":"Advanced melanoma with tumour cell PD-L1 expression below 1%","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Opdualag","company_name":"Australian & New Zealand Children's Haematology/Oncology Group","drug_phase":"marketed","molecular_target":"Lymphocyte activation gene 3 protein","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"bendamustin","indication_name":"Indolent B-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bendamustin","company_name":"Meir Medical Center","drug_phase":"marketed","molecular_target":"Histone deacetylase 1, Histone deacetylase 10, Histone deacetylase 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"bendamustin","indication_name":"Treatment prior to tumor-specific T-cell infusion therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bendamustin","company_name":"Meir Medical Center","drug_phase":"marketed","molecular_target":"Histone deacetylase 1, Histone deacetylase 10, Histone deacetylase 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolone","indication_name":"Giant cell arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednisolone","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"proleukin","indication_name":"Metastatic renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Proleukin","company_name":"University of Minnesota","drug_phase":"marketed","molecular_target":"Interleukin-2 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"lenali","indication_name":"Mantle cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lenali","company_name":"Singapore General Hospital","drug_phase":"marketed","molecular_target":"Bromodomain-containing protein 4, Protein cereblon, Tumor necrosis factor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"neulasta","indication_name":"Allogeneic peripheral blood stem cell transplant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Neulasta","company_name":"Columbia University","drug_phase":"marketed","molecular_target":"Granulocyte colony-stimulating factor receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ontak","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ontak","company_name":"The University of Texas Health Science Center at San Antonio","drug_phase":"marketed","molecular_target":"Interleukin-2 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ontak","indication_name":"Refractory peripheral T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ontak","company_name":"The University of Texas Health Science Center at San Antonio","drug_phase":"marketed","molecular_target":"Interleukin-2 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"isophosphamide","indication_name":"Testicular Germ Cell Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Isophosphamide","company_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","drug_phase":"phase_2","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"fludara","indication_name":"Mantle cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fludara","company_name":"Celyad Oncology SA","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 5A, mitochondrial, DNA polymerase alpha catalytic subunit, Ribonucleoside-diphosphate reductase large subunit","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolon","indication_name":"Giant cell arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolon","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"rabeprazol","indication_name":"Systemic mast cell disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rabeprazol","company_name":"Janssen-Cilag, S.A.","drug_phase":"discontinued","molecular_target":"Sterile alpha and TIR motif-containing protein 1, ATP-binding cassette sub-family G member 2, Adenosine receptor A3","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"busulfex","indication_name":"Autologous hematopoietic stem-cell transplantation for Ewing's sarcoma family of tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"busulfex","company_name":"Dana-Farber Cancer Institute","drug_phase":"marketed","molecular_target":"Matrix metalloproteinase-9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"busulphan","indication_name":"Autologous hematopoietic stem-cell transplantation for Ewing's sarcoma family of tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Busulphan","company_name":"University of Birmingham","drug_phase":"discontinued","molecular_target":"Matrix metalloproteinase-9","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"revlimid","indication_name":"Mantle cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Revlimid","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"Bromodomain-containing protein 4, Protein cereblon, Tumor necrosis factor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"etoposid","indication_name":"Treatment prior to tumor-specific T-cell infusion therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Etoposid","company_name":"University of Ulm","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2, Multidrug resistance-associated protein 6","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolon","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methylprednisolon","company_name":"Leiden University Medical Center","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ifosfamid","indication_name":"Testicular Germ Cell Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ifosfamid","company_name":"Polish Lymphoma Research Group","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cromoglycate","indication_name":"Systemic mast cell disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cromoglycate","company_name":"Vishwajit Nimgaonkar, MD PhD","drug_phase":"phase_3","molecular_target":"Protein S100-P, G-protein coupled receptor 35, Taste receptor type 2 member 20","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"epcoritamab-bysp","indication_name":"Relapsed or refractory diffuse large B-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"EPKINLY","generic_name":"EPCORITAMAB-BYSP","company_name":"GENMAB US, INC.","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20, T-cell surface glycoprotein CD3","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"mometasone","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MOMETASONE","company_name":"","drug_phase":"discontinued","molecular_target":"Multidrug resistance protein 1, Glucocorticoid receptor, Progesterone receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":"12.1 Mechanism of Action Mometasone furoate nasal spray is a corticosteroid demonstrating potent anti-inflammatory properties. The precise mechanism of corticosteroid action on allergic rhinitis is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation. In two clinical studies utilizing nasal antigen challenge, mometasone furoate nasal spray decreased some markers of the early- and late-phase allergic response. These observations included decreases (vs. placebo) in histamine and eosinophil cationic protein levels, and reductions (vs. baseline) in eosinophils, neutrophils, and epithelial cell adhesion proteins. The clinical significance of these findings is not known. The effect of mometasone furoate nasal spray on nasal mucosa following 12 months of treatment was examined in 46 patients with allergic rhinitis. There was no evidence of atrophy and there was a marked reduction in intraepithelial eosinophilia and inflammatory cell infiltration (e.g., eosinophils, lymphocytes, monocytes, neutrophils, and plasma cells)."},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"zanubrutinib","indication_name":"Mantle cell lymphoma (MCL)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brukinsa","generic_name":"ZANUBRUTINIB","company_name":"BeiGene","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":33,"revenue":null,"mechanism":null},{"drug_id":"bevacizumab-maly","indication_name":"Metastatic Renal Cell Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ALYMSYS","generic_name":"BEVACIZUMAB-MALY","company_name":"AMNEAL PHARMS LLC","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"tagraxofusp","indication_name":"Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Molecule 129","generic_name":"TAGRAXOFUSP","company_name":"Stemline Therapeeutics Inc","drug_phase":"marketed","molecular_target":"Elongation factor 2","drug_class":"CD123 Interaction [EPC]","quality_score":10,"revenue":null,"mechanism":"Tagraxofusp works by binding to CD123 on cancer cells, causing them to die."},{"drug_id":"mechlorethamine","indication_name":"Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Valchlor","generic_name":"MECHLORETHAMINE","company_name":"Recordati","drug_phase":"marketed","molecular_target":"","drug_class":"Alkylating Drug [EPC]","quality_score":70,"revenue":null,"mechanism":"Valchlor works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and ultimately leading to cell death."},{"drug_id":"romidepsin","indication_name":"Cutaneous T-cell lymphoma (CTCL)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Istodax","generic_name":"ROMIDEPSIN","company_name":"Teva Pharms Usa Inc","drug_phase":"marketed","molecular_target":"HDACs","drug_class":"Histone Deacetylase Inhibitor","quality_score":62,"revenue":null,"mechanism":"Romidepsin inhibits HDACs, leading to increased acetylation of histones and non-histone proteins, causing cell cycle arrest and apoptosis in cancer cells."},{"drug_id":"filgrastim-txid","indication_name":"Progenitor Cell Mobilization","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"NYPOZI","generic_name":"FILGRASTIM-TXID","company_name":"TANVEX BIOPHARMA USA INC","drug_phase":"marketed","molecular_target":"Specific cell surface receptors on hematopoietic cells","drug_class":"Leukocyte Growth Factor [EPC]","quality_score":50,"revenue":null,"mechanism":"G-CSF binds to specific receptors on hematopoietic cells, stimulating neutrophil production and function."},{"drug_id":"chembl-chembl1789844","indication_name":"First-Line Unresectable or Metastatic Hepatocellular Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IPILIMUMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1789844","indication_name":"Previously Treated Unresectable or Metastatic Hepatocellular Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IPILIMUMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1789844","indication_name":"Metastatic Non-Small Cell Lung Cancer (PD-L1 ≥1%)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IPILIMUMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1789844","indication_name":"Metastatic or Recurrent Non-Small Cell Lung Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IPILIMUMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1789844","indication_name":"Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IPILIMUMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl3833373","indication_name":"Metastatic Merkel Cell Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"AVELUMAB","company_name":"","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Programmed Death Ligand-1 Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":"Avelumab binds to PD-L1, blocking its interaction with PD-1 and B7.1 receptors, restoring immune responses against tumors."},{"drug_id":"chembl-chembl1201576","indication_name":"Previously Untreated Diffuse Large B-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"RITUXIMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CD20-directed Cytolytic Antibody [EPC]","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1946170","indication_name":"Hepatocellular Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"REGORAFENIB","company_name":"","drug_phase":"marketed","molecular_target":"RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2, TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAF V600E, SAPK2, PTK5, Abl, CSF1R","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Regorafenib inhibits multiple kinases involved in oncogenesis, angiogenesis, metastasis, and tumor immunity."},{"drug_id":"chembl-chembl359744","indication_name":"Metastatic Transitional Cell Bladder Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DOXORUBICIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"topoisomerase II","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA, inhibiting nucleotide replication, and forming DNA-cleavable complexes with topoisomerase II."},{"drug_id":"l-carnitine","indication_name":"Mobilization of fat deposits and cellulite","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"L-carnitine","company_name":"Asan Medical Center","drug_phase":"marketed","molecular_target":"","drug_class":"Carnitine Analog [EPC]","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"l-carnitine","indication_name":"Mobilization of fat deposits and cellulite","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"L-carnitine","company_name":"Asan Medical Center","drug_phase":"marketed","molecular_target":"","drug_class":"Carnitine Analog [EPC]","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"ifosfamide","indication_name":"Third-line chemotherapy for germ cell testicular cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ifex","generic_name":"IFOSFAMIDE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"","drug_class":"Alkylating Drug [EPC]","quality_score":70,"revenue":null,"mechanism":"Ifosfamide is activated by liver enzymes to form cytotoxic compounds that cause DNA crosslinks, leading to cell death."},{"drug_id":"sulfur-colloid","indication_name":"Imaging reticuloendothelial cells","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Sulfur Colloid","company_name":"University of California, San Diego","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":35,"revenue":null,"mechanism":"Technetium Tc 99m Sulfur Colloid is used for imaging by entering lymphatic capillaries, mixing with peritoneal fluid, or being taken up by the reticuloendothelial system."},{"drug_id":"sulfur-colloid","indication_name":"Imaging reticuloendothelial cells","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Sulfur Colloid","company_name":"University of California, San Diego","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":35,"revenue":null,"mechanism":"Technetium Tc 99m Sulfur Colloid is used for imaging by entering lymphatic capillaries, mixing with peritoneal fluid, or being taken up by the reticuloendothelial system."},{"drug_id":"flumetasone","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Flucorticin","generic_name":"flumetasone","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"flumetasone","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"alclometasone-dipropionate","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aclovate","generic_name":"ALCLOMETASONE DIPROPIONATE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic esophageal squamous cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic hepatocellular carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic diffuse large B-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic mantle cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic cutaneous squamous cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"imetelstat","indication_name":"low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rytelo","generic_name":"IMETELSTAT","company_name":"Geron","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Rytelo works by inhibiting the activity of telomerase, an enzyme that helps cancer cells grow and divide."},{"drug_id":"brigatinib","indication_name":"Advanced/recurrent anaplasticlymphoma kinase (ALK)-positive non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alunbrig","generic_name":"brigatinib","company_name":"Takeda","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Alunbrig works by blocking the activity of the ALK tyrosine kinase receptor, which is involved in the growth and spread of cancer cells."},{"drug_id":"ensartinib","indication_name":"ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ensacove","generic_name":"ENSARTINIB","company_name":"Xcovery","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":49,"revenue":null,"mechanism":"Ensartinib works by inhibiting a specific protein that drives the growth of cancer cells."},{"drug_id":"valemetostat","indication_name":"Relapsed or refractory T-cell leukemia-lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ezharmia","generic_name":"VALEMETOSTAT","company_name":"Daiichi Sankyo","drug_phase":"marketed","molecular_target":"Histone-lysine N-methyltransferase EZH2","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"cosibelimab","indication_name":"metastatic cutaneous squamous cell carcinoma (mCSCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unloxcyt","generic_name":"COSIBELIMAB","company_name":"Checkpoint Therapeutics Inc","drug_phase":"marketed","molecular_target":"Pd-1","drug_class":"Programmed Death Ligand-1 Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":"Unloxcyt blocks the PD-1/PD-L1 pathway to help the immune system recognize and attack cancer cells."},{"drug_id":"deruxtecan","indication_name":"Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Datroway","generic_name":"DERUXTECAN","company_name":"Daiichi Sankyo","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":44,"revenue":null,"mechanism":"Deruxtecan works by binding to and inhibiting the growth of cancer cells."},{"drug_id":"fludroxycortide","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cordran","generic_name":"fludroxycortide","company_name":"Aqua Pharms","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avastin","indication_name":"Metastatic renal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avastin","company_name":"Washington University School of Medicine","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"narsoplimab","indication_name":"hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Yartemlea","generic_name":"NARSOPLIMAB","company_name":"Omeros Corp","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":40,"revenue":null,"mechanism":"Narsoplimab works by targeting and modulating the immune system to prevent damage to blood vessels."},{"drug_id":"tarlatamab","indication_name":"extensive stage small cell lung cancer (ES-SCLC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imdelltra (Amg757)","generic_name":"TARLATAMAB","company_name":"Amgen Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Imdeldtra works by binding to a specific target on cancer cells, which helps to slow or stop the growth of the cancer."},{"drug_id":"tarlatamab","indication_name":"extensive stage small cell lung cancer (ES-SCLC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imdelltra (Amg757)","generic_name":"TARLATAMAB","company_name":"Amgen Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Imdeldtra works by binding to a specific target on cancer cells, which helps to slow or stop the growth of the cancer."},{"drug_id":"panobinostat","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Farydak","generic_name":"PANOBINOSTAT","company_name":"Secura","drug_phase":"marketed","molecular_target":"Histone deacetylase 4","drug_class":"Histone Deacetylase Inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"forodesine","indication_name":"Peripheral T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immucillin H","generic_name":"FORODESINE","company_name":"Mundi Pharma","drug_phase":"marketed","molecular_target":"Purine nucleoside phosphorylase","drug_class":"","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"ceritinib","indication_name":"ALK fusion gene-positive non-small-cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zykadia","generic_name":"ceritinib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Zykadia blocks the activity of the ALK protein, which is involved in the growth and spread of cancer cells."},{"drug_id":"mechlorethamine","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Valchlor","generic_name":"MECHLORETHAMINE","company_name":"Recordati","drug_phase":"marketed","molecular_target":"","drug_class":"Alkylating Drug [EPC]","quality_score":70,"revenue":null,"mechanism":"Valchlor works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and ultimately leading to cell death."},{"drug_id":"etoposide","indication_name":"Treatment prior to tumor-specific T-cell infusion therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vepesid","generic_name":"etoposide","company_name":"Bristol-Myers Squibb K.K.","drug_phase":"marketed","molecular_target":"DNA topoisomerase 2-alpha","drug_class":"Topoisomerase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"desoximetasone","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Topicort","generic_name":"DESOXIMETASONE","company_name":"Taro","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cefotaxime","indication_name":"Bacteroides Pelvic Cellulitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Claforan","generic_name":"CEFOTAXIME","company_name":"Sterimax","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"cefotaxime","indication_name":"Clostridium Pelvic Cellulitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Claforan","generic_name":"CEFOTAXIME","company_name":"Sterimax","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"cefotaxime","indication_name":"Enterococcus Pelvic Cellulitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Claforan","generic_name":"CEFOTAXIME","company_name":"Sterimax","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"fluocinolone-acetonide","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Derma-Smoothe/Fs","generic_name":"FLUOCINOLONE ACETONIDE","company_name":"Eurofarma","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"bexarotene","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Targretin","generic_name":"BEXAROTENE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Retinoic acid receptor RXR-beta","drug_class":"Retinoid [EPC]","quality_score":10,"revenue":null,"mechanism":"Targretin works by binding to the retinoic acid receptor RXR-beta, which helps regulate cell growth and differentiation."},{"drug_id":"bleomycin","indication_name":"Testicular Germ Cell Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Blenoxane","generic_name":"BLEOMYCIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Aspartyl/asparaginyl beta-hydroxylase","drug_class":"Cytoprotective Agent","quality_score":62,"revenue":null,"mechanism":"Bleomycin works by binding to DNA and causing strand breaks, which ultimately leads to cell death."},{"drug_id":"clocortolone-pivalate","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cloderm","generic_name":"CLOCORTOLONE PIVALATE","company_name":"Legacy Pharma","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"mobocertinib","indication_name":"Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Exkivity","generic_name":"MOBOCERTINIB","company_name":"Takeda","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-4","drug_class":"Kinase Inhibitor","quality_score":28,"revenue":null,"mechanism":""},{"drug_id":"temsirolimus","indication_name":"Mantle cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Torisel","generic_name":"temsirolimus","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase mTOR","drug_class":"Kinase Inhibitor","quality_score":60,"revenue":null,"mechanism":"Torisel works by blocking the mTOR protein, which is involved in cell growth and division."},{"drug_id":"cortisone-acetate","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"ulobetasol-propionate","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ultravate","generic_name":"ulobetasol propionate","company_name":"Ranbaxy","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"ulobetasol propionate","quality_score":10,"revenue":null,"mechanism":"Ultravate works by binding to the glucocorticoid receptor, triggering a cascade of anti-inflammatory effects that reduce skin inflammation."},{"drug_id":"betamethasone-dipropionate","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diprolene","generic_name":"BETAMETHASONE DIPROPIONATE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":51,"revenue":null,"mechanism":"Diprolene works by binding to the glucocorticoid receptor in the skin, which reduces inflammation and suppresses the immune system."},{"drug_id":"cisplatin","indication_name":"Testicular Germ Cell Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Platinol-Aq","generic_name":"cisplatin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"D(3) dopamine receptor","drug_class":"Platinum-based Drug [EPC]","quality_score":52,"revenue":null,"mechanism":""},{"drug_id":"plerixafor","indication_name":"Peripheral Mobilization of Hematopoietic Stem Cells","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mozobil","generic_name":"plerixafor","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"C-C chemokine receptor type 2","drug_class":"Hematopoietic Stem Cell Mobilizer [EPC]","quality_score":61,"revenue":null,"mechanism":"Mozobil works by binding to the C-C chemokine receptor type 2, which helps to mobilize hematopoietic stem cells from the bone marrow into the bloodstream."},{"drug_id":"telisotuzumab","indication_name":"locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Emrelis","generic_name":"TELISOTUZUMAB","company_name":"Abbvie Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Emrelis binds to the c-Met protein on cancer cells, blocking its growth-promoting signals."},{"drug_id":"betamethasone-valerate","indication_name":"Primary cutaneous T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betamethasone Valerate","generic_name":"BETAMETHASONE VALERATE","company_name":"Fougera Pharms Inc","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"fludarabine-phosphate","indication_name":"Mantle cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fludara","generic_name":"FLUDARABINE PHOSPHATE","company_name":"Nihon Schering K.K.","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 5A, mitochondrial","drug_class":"Nucleoside Metabolic Inhibitor","quality_score":65,"revenue":null,"mechanism":"Fludara works by interfering with the production of DNA and RNA in cancer cells, ultimately leading to cell death."},{"drug_id":"bendamustine","indication_name":"Indolent B-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Treanda","generic_name":"BENDAMUSTINE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Histone deacetylase 6","drug_class":"Alkylating Drug","quality_score":63,"revenue":null,"mechanism":"Treanda works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and grow."},{"drug_id":"bendamustine","indication_name":"Treatment prior to tumor-specific T-cell infusion therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Treanda","generic_name":"BENDAMUSTINE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Histone deacetylase 6","drug_class":"Alkylating Drug","quality_score":63,"revenue":null,"mechanism":"Treanda works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and grow."},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Mantle Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Diffuse Large B-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Hairy Cell Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Cutaneous T-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Peripheral T-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory T-Cell Large Granular Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Mantle Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Diffuse Large B-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Hairy Cell Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Cutaneous T-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Peripheral T-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory T-Cell Large Granular Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Mantle Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Diffuse Large B-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Hairy Cell Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Cutaneous T-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Peripheral T-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory T-Cell Large Granular Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Mantle Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Diffuse Large B-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Hairy Cell Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Cutaneous T-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Peripheral T-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory T-Cell Large Granular Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Mantle Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Diffuse Large B-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Hairy Cell Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Cutaneous T-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Peripheral T-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory T-Cell Large Granular Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Mantle Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Diffuse Large B-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Hairy Cell Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[{"drug_id":"pd-0332991","indication_name":"Advanced Hepatocellular Carcinoma","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PD-0332991","generic_name":"pd-0332991","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha, Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, Serine/threonine-protein kinase TAO2","drug_class":"PD-0332991, 125mg, 3 cycles","quality_score":null,"revenue":null,"mechanism":"PD-0332991, 125mg, 3 cycles"},{"drug_id":"pf-07820435","indication_name":"Advanced solid tumors (non-small-cell lung cancer, melanoma)","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07820435","generic_name":"pf-07820435","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"SARS-CoV-2 3CL protease (main protease) and/or cellular proteases in oncology indications","drug_class":"Protease inhibitor","quality_score":null,"revenue":null,"mechanism":"PF-07820435 inhibits viral or cellular proteases to disrupt essential enzymatic processes required for viral replication or tumor cell survival."},{"drug_id":"lorviqua","indication_name":"Metastatic ALK+ Non Small Cell Lung Cancer","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lorviqua","generic_name":"lorviqua","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"Tyrosine-protein kinase FRK, ALK tyrosine kinase receptor, Activated CDC42 kinase 1","drug_class":"As provided in real world practice","quality_score":0,"revenue":null,"mechanism":"As provided in real world practice"}],"offLabel":[],"totalMarketed":605,"totalPipeline":3},"trials":{"data":[{"nct_id":"NCT04471493","title":"Pediatric and Ambulatory Research in Infectious Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":400000,"lead_sponsor_name":"Association Clinique Thérapeutique Infantile du val de Marne","has_results":false},{"nct_id":"NCT03944447","title":"Outcomes Mandate National Integration With Cannabis as Medicine","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":200000,"lead_sponsor_name":"OMNI Medical Services, LLC","has_results":false},{"nct_id":"NCT06820515","title":"ATHNdataset Registry","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":200000,"lead_sponsor_name":"American Thrombosis and Hemostasis Network","has_results":false},{"nct_id":"NCT04969419","title":"Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo","phase":"","overall_status":"COMPLETED","enrollment_count":75771,"lead_sponsor_name":"Momentum Data","has_results":true},{"nct_id":"NCT02402244","title":"Project: Every Child for Younger Patients With Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":75000,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT03892967","title":"Enhanced, EHR-facilitated Cancer Symptom Control Pragmatic Clinical Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":50207,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT03840928","title":"PatientSpot Formerly Known as ArthritisPower","phase":"","overall_status":"UNKNOWN","enrollment_count":40000,"lead_sponsor_name":"Global Healthy Living Foundation","has_results":false},{"nct_id":"NCT06065852","title":"National Registry of Rare Kidney Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"UK Kidney Association","has_results":false},{"nct_id":"NCT02623712","title":"The Watch the Spot Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":34686,"lead_sponsor_name":"Kaiser Permanente","has_results":false},{"nct_id":"NCT07532564","title":"Risk Factors, Costs, and Impacts of ED Boarding","phase":"","overall_status":"COMPLETED","enrollment_count":30486,"lead_sponsor_name":"University of Maryland, Baltimore","has_results":false},{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT06248580","title":"Find HDV and Determine Its Status in Turkey","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Yaşar Bayındır, MD","has_results":false},{"nct_id":"NCT00830557","title":"Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04525833","title":"Liver Disease and Other Systemic Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation","has_results":false},{"nct_id":"NCT04500600","title":"Well-Being and Health-Related Quality of Life in Cancer Patients and Survivors During the COVID-19 Pandemic","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":13378,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06186856","title":"Epidemiological Data on Mast Cell Pathologies in France","phase":"","overall_status":"RECRUITING","enrollment_count":13000,"lead_sponsor_name":"Imagine Institute","has_results":false},{"nct_id":"NCT05227534","title":"Multi-canceR Early-detection Test in Asymptomatic Individuals (PREVENT)","phase":"NA","overall_status":"RECRUITING","enrollment_count":12500,"lead_sponsor_name":"Guangzhou Burning Rock Dx Co., Ltd.","has_results":false},{"nct_id":"NCT03706742","title":"STOP HCC: Mailed HCV Treatment Outreach Program for HCC Prevention","phase":"NA","overall_status":"COMPLETED","enrollment_count":12386,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT03047369","title":"The Myelin Disorders Biorepository Project","phase":"","overall_status":"RECRUITING","enrollment_count":12000,"lead_sponsor_name":"Children's Hospital of Philadelphia","has_results":false},{"nct_id":"NCT06996249","title":"Prospective Data Collection Initiative on Thoracic Malignancies","phase":"","overall_status":"RECRUITING","enrollment_count":12000,"lead_sponsor_name":"Dutch Society of Physicians for Pulmonology and Tuberculosis","has_results":false},{"nct_id":"NCT01772771","title":"Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program","phase":"","overall_status":"RECRUITING","enrollment_count":12000,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05355662","title":"Prognosis Analysis of Elderly Donor Liver in Liver Transplantation","phase":"","overall_status":"COMPLETED","enrollment_count":11569,"lead_sponsor_name":"First Affiliated Hospital Xi'an Jiaotong University","has_results":false},{"nct_id":"NCT06241326","title":"Immunotherapy for Hepatocellular Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":11000,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT07153783","title":"Interventional AI-Human Collaboration for Liver Tumor Diagnosis","phase":"NA","overall_status":"COMPLETED","enrollment_count":10333,"lead_sponsor_name":"Shengjing Hospital","has_results":false},{"nct_id":"NCT06859840","title":"LEAF(Liver Tumor dEtection And classiFication AI)","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT04806620","title":"Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Brain Inflammation Collaborative","has_results":false},{"nct_id":"NCT03517332","title":"Circulating Tumor DNA Exposure in Peripheral Blood","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Quantgene Inc.","has_results":false},{"nct_id":"NCT03588442","title":"Prospective Surveillance for Very Early Hepatocellular Carcinoma","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Eastern Hepatobiliary Surgery Hospital","has_results":false},{"nct_id":"NCT04170257","title":"Performance of White Light, NBI and Iodine Staining Endoscopy in the Diagnosis of Esophageal Lesions","phase":"NA","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT05907447","title":"A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT06766552","title":"A Registry Study Assessing PRO, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases.","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT07358910","title":"Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Institut Pasteur du Cambodge","has_results":false},{"nct_id":"NCT04056247","title":"Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"OncoHost Ltd.","has_results":false},{"nct_id":"NCT04442334","title":"The European NAFLD Registry","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Newcastle University","has_results":false},{"nct_id":"NCT07065201","title":"DENIM-trial: Digital prE-operative patieNt guIdance systeM","phase":"NA","overall_status":"COMPLETED","enrollment_count":10000,"lead_sponsor_name":"Jeroen Bosch Ziekenhuis","has_results":false},{"nct_id":"NCT03851445","title":"Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":false},{"nct_id":"NCT07349498","title":"Cardiovascular Outcomes and Risk Evaluation Among Recipients of Hematopoietic Stem Cell Transplantation","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT05315908","title":"COVID-19 Testing in Underserved and Vulnerable Populations","phase":"NA","overall_status":"TERMINATED","enrollment_count":9120,"lead_sponsor_name":"Jesse Nodora","has_results":true},{"nct_id":"NCT03210935","title":"French National Database of Rare Dermatological Cancers","phase":"","overall_status":"UNKNOWN","enrollment_count":9000,"lead_sponsor_name":"University Hospital, Lille","has_results":false},{"nct_id":"NCT02194738","title":"Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":8300,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06061328","title":"Project OASIS: Optimizing Approaches to Select Implementation Strategies","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":8020,"lead_sponsor_name":"VA Office of Research and Development","has_results":false},{"nct_id":"NCT00898365","title":"Study of Kidney Tumors in Younger Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":8000,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT00068003","title":"Harvesting Cells for Experimental Cancer Treatments","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":7000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07157085","title":"AI Multitask Model for HCC Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":7000,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT05687474","title":"Baby Detect : Genomic Newborn Screening","phase":"","overall_status":"COMPLETED","enrollment_count":6824,"lead_sponsor_name":"Centre Hospitalier Universitaire de Liege","has_results":false},{"nct_id":"NCT02465060","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6452,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04057521","title":"Coordinated HEalthcare for Complex Kids","phase":"NA","overall_status":"COMPLETED","enrollment_count":6259,"lead_sponsor_name":"University of Illinois at Chicago","has_results":false},{"nct_id":"NCT03869619","title":"REal World Data in LYmphoma and Survival in Adults","phase":"","overall_status":"RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT06084234","title":"National Liver Cancer Screening Trial","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":5500,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT06339255","title":"Italian Observational Study on CAR-T Therapy for Lymphoma","phase":"","overall_status":"RECRUITING","enrollment_count":5300,"lead_sponsor_name":"Paolo Corradini","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}